Theratechnologies CEO retires; Amorfix’s steps down

Yves Rosconi, CEO and President of Theratechnologies (TSX:TH), has informed the board of his decision to retire on Dec. 31, 2010, saying he deferred his decision until the company’s lead tesamorelin product was in the final stages of the FDA approval process. A strategic committee of the board will immediately begin the formal search for [...]

Amorfix has Alzheimer’s disease blood screening breakthrough

Amorfix Life Sciences (TSX:AMF) has detected Alzheimer’s disease-associated aggregated Beta-amyloid (ABeta), the hallmark of the disease, in the blood of transgenic mice, including both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD. “This milestone achievement represents the first time that [...]